MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...
Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback